Immuneering Corp is UNDERVALUED at 15.32 per share with modest projections ahead.
Immuneering Corp holds Efficiency (Sharpe) Ratio of -0.21, which attests that the entity had -0.21% of return per unit of risk over the last 3 months. Macroaxis standpoint towards determining the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Immuneering Corp exposes twenty-eight different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to check out Immuneering Corp
market risk adjusted performance of
(3.54), and Risk Adjusted Performance of
(0.27) to validate the risk estimate we provide.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Immuneering Corp income statement, its balance sheet, and the statement of cash flows. Potential Immuneering Corp investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Immuneering Corp investors may use each financial statement separately, they are all related. The changes in Immuneering Corp's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immuneering Corp's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Immuneering Corp
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Immuneering Corp performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Immuneering Corp shares is the value that is considered the true value of the share. If
the intrinsic value of Immuneering is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Immuneering Corp. Please read more on our
fundamental analysis page.
How effective is Immuneering Corp in utilizing its assets?
Immuneering Corp reports assets on its Balance Sheet. It represents the amount of Immuneering resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Immuneering Corp aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Immuneering volatility, please check the breakdown of all its
fundamentals.
Are Immuneering Corp Earnings Expected to grow?
The
future earnings power of Immuneering Corp involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Immuneering Corp factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Immuneering Corp
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Immuneering
expected earnings.
A Deeper Perspective
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Immuneering Corp is not uncomon. Institutional investor usually refers to an organization that invests money in Immuneering Corp on behalf of clients or other money managers. Buying and selling of large positions of Immuneering Corp stock by institutional investors can create supply and demand imbalances that result in sudden price moves of Immuneering Corp stock. Let's take a look at how the ownership of Immuneering is distributed among investors.
Ownership Allocation
Immuneering Corp Cl has a total of twenty-six million three hundred twenty thousand
outstanding shares. Immuneering Corp secures significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Retail Investors25.09% | Insiders28.17% | Institutions46.74% |
| Retail Investors | 25.09 |
| Insiders | 28.17 |
| Institutions | 46.74 |
Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Immuneering suggests not a very effective usage of assets in April.
| Current Assets | 164.36 Million | 88.24 |
| Assets Non Current | 15.51 Million | 8.32 |
| Goodwill | 6.39 Million | 3.43 |
Will Immuneering Corp current rise continue?
Coefficient Of Variation just dropped to -381.64, may suggest upcoming price decrease. Immuneering Corp Cl exhibits very low volatility with skewness of 0.19 and kurtosis of -0.64. However, we advise investors to further study Immuneering Corp Cl technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immuneering Corp's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immuneering Corp's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Immuneering Corp Implied Volatility
Immuneering Corp's implied volatility exposes the market's sentiment of Immuneering Corp Cl stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immuneering Corp's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immuneering Corp stock will not fluctuate a lot when Immuneering Corp's options are near their expiration.
Our Bottom Line On Immuneering Corp
While few other entities in the biotechnology industry are either recovering or due for a correction, Immuneering may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Immuneering nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Immuneering Corp.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Immuneering Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com